SAN FRANCISCO (MedPage Today) -- An oral fluoropyrimidine called S-1 increased overall survival compared with adjuvant gemcitabine therapy in a phase III trial of Japanese patients with resected pancreatic cancer, researchers reported here. via MedPageToday.com - medical news plus CME for physicians Read More Here..
No comments:
Post a Comment